Colorectal Cancer Screening

Screening asymptomatic, average-risk persons for CRC — distinct from the diagnostic workup and staging of an already-diagnosed cancer (see Colorectal Cancer Staging (TNM) for that topic). Choice of screening modality is a genuinely confusing discussion for physician and patient alike; factors to weigh include family history/hereditary-syndrome risk (see Hereditary Colorectal Cancer Syndromes), personal IBD history, comorbidities, age/life expectancy, risk tolerance/anxiety, healthcare access, compliance likelihood, and insurance coverage/cost. Source: ASCRS Ch24 - Colorectal Cancer Preoperative Evaluation and Staging — textbook reference content, not primary literature.

Summary comparison of modalities

Fecal sampling

The least invasive, most widely available screening option, avoiding mechanical bowel preparation and more practical where endoscopy access is poor. These tests do not replace endoscopy — a positive result should prompt colonoscopy — but can conserve colonoscopy capacity for a smaller, enriched-risk population.

• FOBT: a guaiac-based test detecting heme (nonprotein hemoglobin portion) — detects blood from any source, including animal blood in the diet. Patients smear stool on a card over 3 different days and mail the cards in; recommended annually. The oldest, least expensive stool test, but requires dietary/medication modification for several days beforehand (avoiding red meat, raw produce, antacids, vitamin C, NSAIDs, loperamide, iron supplements; menstruation is a relative contraindication) — these restrictions and lower specificity have made it less attractive than newer stool tests.
• FIT (fecal immunochemical test, a.k.a. "safety-chemical" method): detects antibodies to the human globin portion of hemoglobin — less cross-reactivity with nonhuman blood, improved specificity over FOBT. Requires only a single card (better compliance); still recommended annually.
• Multitarget stool DNA-FIT (Cologuard): combines the FIT test with detection of genetic mutations found in cancer cells (KRAS, NDRG4, BMP3, β-actin). 13% false-positive, 8% false-negative rate; recommended every 3 years; approved for use in 2014; relatively expensive ($649 out-of- pocket) and may not be covered by insurance; cannot differentiate between advanced polyps and adenocarcinoma.

Flexible sigmoidoscopy

Examines the distal colon in an office setting with minimal preparation, without sedation; can extend beyond 25 cm and is typically more easily tolerated than rigid proctoscopy. Suggested as a screening tool in younger adults (higher incidence of left-sided cancers in this population) and was historically used with barium enema; insufficient alone in older individuals given the age-related shift of polyps/cancers to the proximal colon, so has been combined with FIT/FOBT to theoretically enhance detection. (See Colonoscopy & Lower GI Endoscopy for procedural/technique detail — independently sourced from a different ASCRS chapter, with similar sensitivity figures for polyp/CRC detection.)

CT colonography (CTC)

"Virtual colonoscopy" — multiple thin-slice CT images after CO₂ colonic insufflation via a rectal tube, typically supine and lateral, reconstructed into 2D/3D mucosal views. Avoids sedation, may be preferable for patients with comorbidities precluding optical colonoscopy or a tortuous colon. Requires full cathartic bowel prep; suspicious findings prompt subsequent optical colonoscopy; radiation exposure and rare contrast-nephropathy risk; comparable sensitivity to colonoscopy for polyps >1 cm but less effective for smaller lesions (difficult to differentiate from stool); associated with abdominal cramping and rare perforation risk; can identify incidental abdominal findings requiring further workup; typically not covered by Medicare and can be difficult to obtain insurance approval for, despite an "A" grade from the USPSTF.

CTC is the procedure of choice for incomplete colonoscopy due to technical limitations or an obstructing lesion, and offers better imaging resolution than traditional fluoroscopic contrast enema. In the setting of a known malignancy, its costs/risks should be weighed against how much treatment decisions would actually change based on findings — e.g., in a patient with an obstructing proximal-colon tumor requiring colectomy, CTC is unlikely to change management since the colon proximal to the tumor will be resected regardless; for a distal obstructing tumor, CTC can help rule out proximal synchronous tumors, though staging CT is a reasonable alternative if the patient's clinical situation allows deferring further synchronous-lesion assessment (e.g., completion colonoscopy after neoadjuvant-therapy tumor shrinkage, prior to surgical resection).

Colonoscopy

The most sensitive and specific test for CRC and polyps — diagnostic (detects polyps/cancers), therapeutic (removes polyps), and preventive (prevents polyp-to-cancer progression); also detects other pathology (IBD, diverticulosis). The most invasive option: requires full bowel prep (nausea, vomiting, abdominal pain, dehydration risk) and carries periprocedural risks including perforation (0.1%), GI bleeding (especially post-biopsy/polypectomy), missed lesions (false negatives), and incomplete procedure (5–10% of the time, knowingly or unknowingly). Quality varies by performing physician's technical expertise; rural areas often have lower-volume providers and longer patient travel times, limiting overall endoscopy access.

If a neoplasm is encountered during colonoscopy, the endoscopist should weigh the benefits of biopsy and tumor localization/tattooing (see Colorectal Cancer Staging (TNM)'s Diagnostic workup section for the localization/tattooing detail). For an obvious adenomatous neoplasm of the intraperitoneal colon clearly requiring colectomy, biopsy results are arguably unlikely to change management and can add unnecessary cost/bleeding/perforation risk plus false-negative confusion — but biopsy may still be helpful to detect Lynch syndrome preoperatively (potentially altering treatment decisions) or to guide chemotherapeutic choice if the patient has incurable distant metastatic disease being treated nonoperatively. If the lesion's etiology is in question (possible lymphoma or ischemic ulcer), biopsy is warranted. If a small tumor is unlikely to be visible from the serosal side intraoperatively, the distal extent should be marked with tattoo to assist intraoperative localization. If a rectal tumor is encountered, biopsy should be performed routinely, including molecular testing/IHC for mismatch repair proteins — rectal cancer patients treated with neoadjuvant radiotherapy/chemotherapy may have tumor altered such that molecular analysis becomes impossible postoperatively, and some medical/radiation oncologists are reluctant to initiate neoadjuvant therapy without histologic confirmation of adenocarcinoma.

Related pages

• Colorectal Cancer Staging (TNM) — the diagnostic workup/staging pathway that begins once screening (or symptomatic presentation) leads to a CRC diagnosis.
• Colonoscopy & Lower GI Endoscopy — general endoscopic technique, bowel prep, and complication detail underlying the colonoscopy/flexible-sigmoidoscopy screening options above.
• Sporadic & Young-Onset Colorectal Cancer — the ACS-vs-NCCN average-risk screening-age discrepancy (45 vs. 50), a related but distinct open guideline conflict from this page's modality- choice content.
• Obstructing Colon Cancer — endoscopic stenting and alternative workup when colonoscopy can't be completed due to an obstructing lesion.
• Hereditary Colorectal Cancer Syndromes — altered screening intervals/ages for hereditary-risk patients, distinct from this page's average-risk framework.

Open items / gaps

• No primary literature yet backing any specific screening modality's performance figures above (all textbook-chapter-sourced); the FIT/FOBT/DNA-FIT sensitivity-specificity figures and CTC accuracy data would benefit from primary-literature or guideline-level (e.g., USPSTF) sourcing.
• Screening intervals/recommendations for hereditary-risk or IBD-risk populations are covered elsewhere (Hereditary Colorectal Cancer Syndromes, Ulcerative Colitis) rather than here — this page is average-risk-only by design, but the cross-reference could be made more explicit if a future chapter covers risk-stratified screening in more depth.